European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care
Approval is based on unprecedented Phase 3 data showing statistically significant improvements in progression-free and overall survival versus…